Syndax Pharmaceuticals
Price & Volume
Stats
See more52W Range | $9.03-$25.59 |
Market Cap | $2.1B |
Shares Short | 19M |
Financials
See moreRevenue (12 Mos) | $217.1M |
Revenue Growth (YoY) | 223.6% |
Gross Profit (12 Mos) | -$50.3M |
Diluted EPS | -$2.79 |
News
See moreYahoo Finance • 11 days ago
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
Yahoo Finance • 18 days ago
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Yahoo Finance • 2 months ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Yahoo Finance • 2 months ago
Syndax outlines 2026 operating expense target of approximately $400M as Revuforj expands in NPM1
About
CEO | Mr. Michael A. Metzger M.B.A. |
CFO | Mr. Keith Alan Goldan CPA |
Address | 730 Third Avenue, New York, NY, United States, 10017 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 298 |